Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 9, 1999, Pages 2126-2130

  Miyazaki, Eishi ^a   Chaisson, Richard E ^a   Bishai, William R ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; DEXAMETHASONE; ISONIAZID; PYRAZINAMIDE; RIFAPENTINE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; FEMALE; INFECTION PREVENTION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS;

EID: 0032824390     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.9.2126     Document Type: Article

References (32)

1. Antonucci, G., E. Girardi, M. C. Raviglione, and G. Ippolito. 1995. Risk factors for tuberculosis in HIV-infected persons: a prospective cohort study. JAMA 274:143-148.
2. Arioli, V., M. Berti, G. Carniti, E. Randisi, E. Rossi, and R. Scotti. 1981. Antibacterial activity of DL473, a new semisynthetic rifamycin derivative. J. Antibiot. (Tokyo) 34:1026-1029.
3. Assandri, A., B. Ratti, and T. Christina. 1984. Pharmacokinetics of rifapentine, a new long lasting rifamycin, in the rat, the mouse and the rabbit. J. Antibiot. (Tokyo). 37:1066-1069.
4. Birmingham, A. T., A. J. Coleman, M. L. S. Orme, B. K. Park, N. J. Pearson, A. H. Short, and P. J. Southgate. 1978. Antibacterial activity in serum and urine following oral administration in man of DL473 (a cyclopentyl derivative of rifampicin). Br. J. Clin. Pharmacol. 6:455P-456P.
5. Chapuis, L., B. Ji, C. Truffot-Pernot, R. J. O'Brien, M. C. Raviglione, and J. H. Grosset. 1994. Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. Am. J. Respir. Crit. Care Med. 150:1355-1362.
6. de Wit, D., M. Wootton, J. Dhillon, and A. Mitchison. 1995. The bacterial DNA content of mouse organs in the Cornell model of dormant tuberculosis. Tuber. Lung Dis. 76:555-562.
7. Dhillon, J., J. M. Dickinson, J. A. Guy, T. K. Ng, and D. A. Mitchison. 1992. Activity of two long-acting rifamycins, rifapentine and FCE 22807, in experimental murine tuberculosis. Tuber. Lung Dis. 73:116-123.
8. Dhillon, J., J. M. Dickinson, K. Sole, and D. A. Mitchison, 1996. Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide. Antimicrob. Agents Chemother. 40: 552-555.
9. Dickinson, J. M., G. A. Ellard, and D. A. Mitchison. 1968. Suitability of isoniazid and ethambutol for intermittent administration in the treatment of tuberculosis. Tubercle 49:351-366.
10. Dickinson, J. M., and D. A. Mitchison. 1987. In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis. Tubercle 68:113-118.
11. Ferebee, S. H. 1970. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv. Tuberc. Res. 17:28-106.
12. Gordin, F. M., and the CPCRA 004/ACTG 177 Investigators. 1998. Preliminary analysis of short-course preventive therapy for tuberculosis in HIV-infected adults. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections.
13. Grosset, J., N. Lounis. C. Truffot-Pernot, R. J. O-Brien, M. C. Raviglione, and B. Ji. 1998. Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice. Am. J. Respir. Crit. Care Med. 157:1436-1440.
14. Halsey, N. A., J. S. Coberly, J. Desormeaux, P. Losikoff, J. Atkinson, L. H. Moulton, M. Cantave, M. Johnson, H. Davis, L. Geiter, E. Johnson, R. Huebner, R. Boulos, and R. E. Chaisson. 1998. Randomised trial of isoniazid versus rifampin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 351:786-791.
15. Heifets, L. B., P. J. Lindholm-Levy, and M. A. Flory. 1990. Bactericidal activity in vitro of various rifamycins against M. avium and M. tuberculosis. Am. Rev. Respir. Dis. 141:626-630.
16. Hong Kong Chest Service and British Medical Research Council. 1992. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am. Rev. Respir. Dis. 145:36-41.
17. Ji, B., C. Truffot-Pernot, C. Lacroix, M. C. Raviglione, R. J. O'Brien, P. Olliaro, G. Roscigno, and J. H. Grosset. 1993. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am. Rev. Respir. Dis. 148:1541-1546.
18. Kochi, A. 1991. The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle 72:1-6.
19. Lecoeur, H. F., C. Truffot-Pernot, and J. H. Grosset. 1989. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am. Rev. Respir. Dis. 140:1189-1193.
20. McCune, R. M., F. M. Feldmann, H. P. Lambert, and W. McDermott. 1966. Microbial persistance. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J. Exp. Med. 123:445-468.
21. Miyazaki, E., M. Miyazaki, J. Chen, R. E. Chaisson, and W. R. Bishai. 1999. Moxifloxacin (BAY 12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob. Agents Chemother. 43:85-89.
22. Mor, N., B. Simon, N. Mezo, and L. Heifets. 1995. Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages. Antimicrob. Agents Chemother. 39:2073-2077.
23. Mwinga, A., M. Hosp, P. Godfrey-Faussett, M. Quigley, P. Mwaba, B. N. Mugala, O. Nyirenda, N. Luo, J. Pobee, A. M. Elliott, K. P. McAdam, and J. D. Porter. 1998. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 12:2447-2457.
24. Narain, J. P., M. C. Raviglione, and A. Kochi. 1992. HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention. Tuber. Lung Dis. 73:311-321.
25. Parrish, N. M., J. D. Dick, and W. R. Bishai. 1998. Mechanisms of latency in Mycobactmum tuberculosis. Trends Microbiol. 6:107-112.
26. Selwyn, P. A., D. Hartel, V. A. Lewis, E. E. Schoenbaum, S. H. Vermund, R. S. Klein, A. T. Walker, and G. H. Friedland. 1989. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N. Engl. J. Med. 320:545-550.
27. Tam, C. M., S. L. Chan, C. W. Lam, J. M. Dickinson, and D. A. Mitchison. 1997. Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong. Int. J. Tuberc. Lung Dis. 1:411-416.
28. Tam, C. M., S. L. Chan, C. W. Lam, C. C. Leung, K. M. Kam, J. S. Morris, and D. A. Mitchison. 1998. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis: initial report. Am. J. Respir. Crit. Care Med. 157:1726-1733.
29. Tuberculosis Chemotherapy Centre. 1970. A controlled comparison of a twice-weekly and three once-weekly regimens in the initial treatment of pulmonary tuberculosis. Bull W. H. O. 43:143.
30. Valway, S. E., M. P. C. Sanchez, T. F. Shinnick, I. Orme, T. Agerton, D. Hoy, J. S. Jones, H. Westmorland, and I. M. Onorato. 1998. An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis. N. Engl. J. Med. 338:633-639.
31. Vernon, A., E. Villarino, L. Geiter, and R. O'Brien. 1997. Design of U.S. Public Health Service (U.S.P.H.S) Study 22: a trial of once weekly isoniazid (INH) and rifapentine (Rpt) in the continuation phase of TB treatment. Am. J. Respir. Crit. Care Med. 155(Part 2):A255.
32. Whalen, C. C., J. L. Johnson, A. Okwera, D. L. Hom, R. Huebner, P. Mugyenyi, R. D. Mugerwa, and J. J. Ellner. 1997. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N. Engl. J. Med. 337:801-808.